Inflammation as Treatment Target for Status Epilepticus

Abstract

Background: Status epilepticus (SE) is a serious neurological disease which manifests itself as prolonged seizures which last more than 5 minutes and between such episodes patients do not regain consciousness. Not only can it result in cognitive defects, but also in brain damage or even death. It is commonly known that one of the causes can be inflammatory process, but here we will focus on inflammation as a result in new onset refractory status epilepticus and related to this, new promising forms of SE treatment. Particular emphasis has been focused on new-onset refractory status epilepticus (NORSE). Methods: Based on public research databases, drugs with anti-inflammatory activity – commonly used in different spheres of medicine – have been reviewed as potentially treating status epilepticus. Results: There is seizable clinical research suggesting that drugs that decrease inflammatory process might be effective in terminating status epilepticus. Conclusion: There is growing evidence that adding anti-inflammatory drugs to basic antiepileptic treatment enhances the efficiency of the therapeutic process, with special potential in NORSE cases

Conditional Knockout of IL-1R1 in Endothelial Cells Attenuates Seizures and Neurodegeneration via Inhibiting Neuroinflammation Mediated by Nrf2/HO-1/NLRP3 Signaling in Status Epilepticus Model

“…Hippocampal damage caused by SE can bring about cognitive impairment [ 43 ]. Correspondingly, several animal models of TLE exhibit memory dysfunction, especially spatial memory impairment [ 44 ].…”